No / Co-crystal screening is routinely undertaken using high-throughput solution growth. We report a low- to medium throughput approach, encompassing both a melt and solution crystallization step as a route to the identification of co-crystals. Prior to solution studies, a melt growth step was included utilizing the Kofler mixed fusion method. This method allowed elucidation of the thermodynamic landscape within the binary phase diagram and was found to increase overall screening efficiency. The pharmaceutically acceptable adduct nicotinamide was selected and screened against a small set of active pharmaceutical ingredients (APIs) (ibuprofen (both the racemic compound (R/S) and S-enantiomer), fenbufen, flurbiprofen (R/S), ketoprofen (R/S), paracetamol, piracetam, and salicylic acid) as part of a larger systematic study of synthon stability. From the screen, three new co-crystal systems have been identified (ibuprofen (R/S and S) and salicylic acid) and their crystal structures determined. Because of poor crystal growth synchrotron radiation was required for structure solution of the S-ibuprofen nicotinamide co-crystal. Two further potential systems have also been discovered (fenbufen and flurbiprofen), but crystals suitable for structure determination have yet to be obtained. A greater ability to control crystallization kinetics is required to yield phase-pure single-crystalline material for full verification of this crystal engineering strategy.

No / Hot melt extrusion is a continuous process with wide industrial applicability. Till current date, there have been no reports on the formulation of extrudates for topical treatment of dermatological diseases. The aim of the present work was to prepare and characterize medicated hot melt extrudates based on Soluplus polymer and nicotinamide, and to explore their applicability in acne treatment. The extrudates were characterized using DSC, FTIR, XRD, and DVS. The extrudates were also tested for their skin adhesion potential, ability to deposit nicotinamide in different skin layers, and their clinical efficacy in acne patients. The 10% nicotinamide extrudates exhibited amorphous nature which was reserved during storage, with no chemical interaction between nicotinamide and Soluplus. Upon contrasting the skin adhesion and drug deposition of extrudates and nicotinamide gel, it was evident that the extrudates displayed significantly higher adhesion and drug deposition reaching 4.8 folds, 5.3 folds, and 4.3 folds more in the stratum corneum, epidermis and dermis, respectively. Furthermore, the extrudates significantly reduced the total number of acne lesions in patients by 61.3% compared to 42.14% with the nicotinamide gel. Soluplus extrudates are promising topical drug delivery means for the treatment of dermatological diseases.

Le nicotinamide est une vitamine fournie par l'alimentation et utilisée en thérapie dans le traitement de certaines pathologies humaines. Chez Leishmania, un protozoaire parasite responsable des leishmanioses, cette vitamine présente une action toxique contre le parasite et une action synergique avec l'antimoine, la principale molécule utilisée dans le traitement des leishmanioses. En recherchant le mode d'action de cette vitamine, nous avons observé qu'elle était en réalité un précurseur essentiel à la synthèse du NAD+ chez le parasite, un cofacteur responsable de la plupart des réactions d'oxydoréduction chez tous les êtres vivants. Leishmania étant en effet dépourvu des voies de synthèse de novo du NAD+, il doit le générer à partir de précurseurs qu'il importe depuis son environnement (nicotinamide, nicotinamide riboside, acide nicotinique). Cette auxotrophie du parasite pour le NAD+ révèle donc un rôle ambivalent du nicotinamide, à la fois toxique à fortes concentrations et pourtant essentiel à sa survie en tant que précurseur majeur du NAD+. À partir des bases de données, nous avons reconstitué l'ensemble de la voie de synthèse du NAD+ chez Leishmania. Parmi les enzymes impliquées, nous avons identifié une nicotinamidase qui n'a pas d'homologue chez les mammifères, et qui assure la conversion du nicotinamide en acide nicotinique, première étape à la synthèse du NAD+. Cette enzyme étant un candidat intéressant pour le développement de molécules ciblant spécifiquement le parasite, nous avons réalisé la caractérisation fonctionnelle de ce gène. Son inactivation induit une diminution importante de la concentration en NAD+ chez le parasite et provoque un arrêt de la prolifération en culture, ainsi qu'une incapacité des mutants à établir une infection durable chez la souris. L'obtention de la structure de la nicotinamidase de L. infantum nous offre désormais la possibilité de développer des inhibiteurs spécifiques contre cette nouvelle cible thérapeutique. / Nicotinamide is a vitamin provided by food that is already used in human therapy. In Leishmania protozoan parasites, this molecule shows toxic activity against parasites and has synergistic activity with antimonials, the main drugs used to treat leishmaniasis. By investigating the mode of action of this cheap vitamin, we discovered that nicotinamide is in fact the main precursor of NAD+ synthesis in Leishmania, a redox cofactor essential for all living cells. Leishmania are indeed devoid of a de novo NAD+ pathway and must synthesize it by scavenging precursors from their environment (nicotinamide, nicotinic acid and nicotinamide riboside). This NAD+ auxotrophy reveals a mixed pattern of activity of nicotinamide in Leishmania, i.e. toxic at high concentrations but also essential for parasite survival through its role in NAD+ synthesis. All enzymes of the Leishmania NAD+ salvage pathway were then identified from genome databases. We focused on a putative nicotinamidase, which has no homolog in mammals and governs the conversion of nicotinamide to nicotinic acid, the first step in the NAD+ salvage pathway. Since this enzyme could be considered as an attractive therapeutic target to develop specific parasite inhibitors, we performed a functional analysis of the corresponding gene. Targeted deletion of the nicotinamidase encoding gene induced a marked drop in parasite NAD+ content and a phenotype with strongly delayed growth. Additionally, these mutants are unable to establish durable infections in mice. The crystal structure of the nicotinamidase from L. infantum will allow us to develop specific inhibitors against this new therapeutic target.

Les co-cristaux représentent une classe de composés offrant de grandes opportunités pour l'industrie pharmaceutique. La plupart des études présentées dans la littérature porte sur le diagramme thermodynamique et sur l'ingénierie cristalline. Ce travail y ajoute l'aspect cinétique qui est essentiel à prendre en compte pour la mise en place d'un procédé de cristallisation à l'échelle industrielle. Différentes techniques d'analyse en ligne ont été mises en oeuvre pour suivre le procédé de co-cristallisation. Le système modèle carbamazépine / nicotinamide a été sélectionné. Dans un premier temps, l'utilisation d'une sonde de visualisation in-situ a permis la construction d'un diagramme de phase pour le système modèle étudié. Par la suite, les chemins cinétiques du procédé de co-cristallisation ont été mesurés en solution grâce au suivi des concentrations en soluté par spectroscopie InfraRouge à Transformée de Fourier. Enfin, la transition entre les phases solides (carbamazépine et cocristaux) a été suivie in-situ par spectroscopie IR et en couplant la sonde de visualisation avec la sonde Lasentec FBRM. Les essais ont permis de vérifier qu'une dérive de procédé conduisant à une autre phase cristalline que les co-cristaux peut être corrigée pour obtenir au final uniquement des co-cristaux / Co-crystals represent a class of compounds, which offers huge opportunities for the pharmaceutical industry. Most studies presented in the literature deals with the thermodynamic diagram and crystal engineering. This work adds the kinetic aspect that must imperatively be taken into account in the establishment of a crystallization process at an industrial case. Different in-line process analytical techniques were carried out to monitor the co-crystallization process. The model system carbamazepine / nicotinamide was selected. The use of an in-situ visualization probe allowed us to build the phase diagram of the model system studied. Afterwards, the kinetic pathways of the co-crystallization process were highlighted thanks to the following of the solute concentrations by Fourier Transform InfraRed spectroscopy. Finally, the phase transition between carbamazepine and co-crystals was monitored by IR spectroscopy, and by using simultaneously the visualization probe with the Lasentec FBRM probe. In order to finally obtain the only co-crystal phase, we subsequently verified that it was possible to correct a situation of process deviation, for which another crystalline phase remained in suspension

Over the past few years the NAD-related compounds nicotinamide (NAM), nicotinamide riboside (NR) and 1-methylnicotinamide (MNA) have been established as important molecules in signalling pathways that contribute to metabolic functions of many cells, including those of the immune system. Among immune cells, monocytes/macrophages, which are the major players of inflammatory processes, are especially susceptible to the anti-inflammatory action of NAM. Here we asked whether NAM and the two other compounds have the potential to regulate differentiation and LPS-induced biological answers of the monocytic cell line THP-1. We show that treatment of THP-1 cells with NAM, NR and MNA resulted in growth retardation accompanied by enrichment of cells in the G0/G1-phase independent of p21 and p53. NAM and NR caused an increase in intracellular NAD concentrations and SIRT1 and PARP1 mRNA expression was found to be enhanced. The compounds failed to up-regulate the expression of the cell surface differentiation markers CD38, CD11b and CD14. They modulated the reactive oxygen species production and primed the cells to respond less effectively to the LPS induced TNF-a production. Our data show that the NAD metabolites interfere with early events associated with differentiation of THP-1 cells along the monocytic path and that they affect LPS-induced biological responses of the cell line.

Over the past few years the NAD-related compounds nicotinamide (NAM), nicotinamide riboside (NR) and 1-methylnicotinamide (MNA) have been established as important molecules in signalling pathways that contribute to metabolic functions of many cells, including those of the immune system. Among immune cells, monocytes/macrophages, which are the major players of inflammatory processes, are especially susceptible to the anti-inflammatory action of NAM. Here we asked whether NAM and the two other compounds have the potential to regulate differentiation and LPS-induced biological answers of the monocytic cell line THP-1. We show that treatment of THP-1 cells with NAM, NR and MNA resulted in growth retardation accompanied by enrichment of cells in the G0/G1-phase independent of p21 and p53. NAM and NR caused an increase in intracellular NAD concentrations and SIRT1 and PARP1 mRNA expression was found to be enhanced. The compounds failed to up-regulate the expression of the cell surface differentiation markers CD38, CD11b and CD14. They modulated the reactive oxygen species production and primed the cells to respond less effectively to the LPS induced TNF-α production. Our data show that the NAD metabolites interfere with early events associated with differentiation of THP-1 cells along the monocytic path and that they affect LPS-induced biological responses of the cell line.

The crystalline solid state is invaluable to both the pharmaceutical and fine chemical sectors. The advantages primarily relate to reducibility criteria required during processing of stable solid state materials and delivering purification, which is inherently performed by the crystal growth process. A major challenge is achieving control through crystallising solids with the desired physico-chemical properties. If this can be achieved the crystalline solid is of great financial and practical benefit. One emerging methodology for manipulating the solid crystalline form is the application of co-crystals. This work relates to key steps in the understanding of rational design of co-crystals utilizing crystal engineering concepts to determine systems before then applying screening criteria to the selected sub-set. Co-crystal screening is routinely undertaken using high-throughput solution growth. We report a low- to medium-throughput approach, encompassing both a melt and solution crystallization step as a route to the identification of co-crystals. Prior to solution studies, a melt growth step was included utilizing the Kofler mixed fusion method. This method allowed elucidation of the thermodynamic landscape within the binary phase diagram and was found to increase overall screening efficiency. This led to the discovery of a number of co-crystal systems with the co-former nicotinamide, with the single crystal structures determined for the following systems; R/S ibuprofen: nicotinamide, S ibuprofen: nicotinamide, R/S flurbiprofen: nicotinamide and salicylic acid: nicotinamide. To assess the crystallization and phase behaviours of determined co-crystals the R/S ibuprofennicotinamide system was selected and successful studies were undertaken determining the aqueous ternary phase behavior and the pre-nucleation speciation in methanol. There have, as yet, been a limited number of published examples which are concerned with pharmaceutical property enhancement by co-crystals, as vast proportion of the literature concerns the growth and isolation of these novel phases. To elucidate further the pharmaceutical relevance of co-crystals the properties of the R/S ibuprofen- nicotinamide system were then assessed showing a positive profile for this material.

Poly(ADP-ribosyl)ation is a reversible post-translational modification of histones and nuclear proteins rapidly stimulated by DNA damage. Its homeostasis is a dynamic process regulated by the synthesizing enzymes poly(ADP-ribose) polymerases (PARPs) and the degrading enzyme poly(ADP-ribose) glycohydrolase (PARG). PARP-1, the first-discovered and major PARP, has been the focus of many studies aimed at clarifying the biological function of poly(ADP-ribose) (PAR). This abundant nuclear enzyme plays key roles in a variety of cellular processes, including the regulation of chromatin structure, transcription and genomic integrity. Its multifunctionality has made it an attractive and potential target for therapy, as evidenced by the numerous PARP-1 inhibitors currently undergoing clinical trials. The transient nature of PAR, explained by the close coordination between PARP-1 and PARG, has also highlighted the potential of targeting PARG for diseases of inappropriate cell death. A number of obstacles, however, have prevented PARG from being studied as extensively as PARP-1. The extreme sensitivity of PARG to proteases and its insolubility at high concentrations have limited structure-activity relationship analyses and structural studies of PARG, and the unavailability of high-throughput activity assays has stalled the discovery and development of specific and cell permeable PARG inhibitors, subsequently slowing down the validation of PARG as a therapeutic target. The work presented in this dissertation describes in detail strategies devised to overcome these difficulties. First, a novel colorimetric high-throughput assay for PARG was evaluated and its sensitivity and precision were compared to a widely-used radiolabelling assay. Second, several expression and purification systems were constructed in order to obtain high quantities of soluble human PARG protein adequate for in vitrostructural studies. The efficacy of these strategies was demonstrated in structure-activity analyses of PARG which led to the identification of a regulatory segment far removed linearly from the catalytic site of PARG. This region, necessary for catalytic activity, corresponds with a recently identified mitochondrial targeting sequence (MTS) and was thus named the ‘regulatory segment/MTS’ (REG/MTS). Finally, based on structural data obtained, secondary structure predictions were made to provide insight into the molecular composition of the different domains of PARG, whose structures still remain to be determined.

Nicotinamide delivered in drinking water at about 2 g/kg/day significantly prolonged survival and showed a suggestive improvement on memory in the Npc1 (nih) / Npc1 (nih) mouse model of infantile NPC1 disease. It is likely that this role is due to its function as a histone deacetylase (HDAC) inhibitor although another HDAC inhibitor, valproic acid, was without effect. Nicotinamide could also work by preventing/reversing oxidative stress.

Nicotinamide cofactors in their reduced and oxidised forms are important redox agents in biology. Of about 3000 dehydrogenases available to date, many require these cofactors for their activity. Dehydrogenases are of interest to chemists as they offer asymmetric catalysis to yield chiral products. The requirement of dehydrogenases for nicotinamide cofactors necessitates research into finding the best way of recycling the oxidised or reduced forms of these cofactors. Electrocatalytic NAD(P)H oxidation and NAD(P)⁺ reduction on standard electrodes is problematic due to unwanted side reactions and high overpotential requirements, but in Nature efficient enzyme catalysts are available to facilitate these reactions. The focus of this Thesis, the Soluble Hydrogenase of R. eutropha (SH) is a multimeric bidirectional hydrogenase that couples H2 oxidation to the reduction of NAD⁺ to NADH. Protein Film Electrochemistry (PFE) has been employed to study NAD⁺-reducing catalytic moieties of the SH for the first time. It is shown that SH subunits on an electrode are able to catalyse NADH oxidation and NAD⁺ reduction efficiently with minimal overpotential, which is significant because in vivo, NAD(H) cycling is coupled to 2H⁺/H₂ cycling and these reactions are closely spaced in potential. Substrate affinities and inhibition constants for the SH, determined using PFE are discussed in the context of the SH function and the related catalytic domains of respiratory Complex I. A range of molecules that are known to inhibit the related Complex I have been investigated for their ability to inhibit the SH moieties: the similarity between inhibition constants is consistent with structural and functional similarity between the SH and Complex I. The ability of the SH moieties to sustain NAD(H) catalysis in the presence of O₂ is also demonstrated and is consistent with the requirement for the SH to function under aerobic conditions and to reactivate the inactivated hydrogenase moiety by supplying low potential electrons from NADH. Engineered variants of the SH, designed to enhance the affinity towards NADP⁺, were investigated for the first time, using PFE. Electrochemical characterisation of the variants is presented and results are discussed alongside findings on the wild type SH. The variants are shown to exhibit NADP⁺ reduction, and to have higher affinity towards NADP⁺ than the wild type SH. The first efficient NADP⁺ reduction and NADPH oxidation is observed for one of the variants on a graphite electrode and the best variant showed a K_M of 1.7 mM for NADP⁺. This Thesis also provides evidence for the ability of moieties of the SH to be used in cofactor regeneration systems. Two novel systems are demonstrated. The first involves H₂ driven NADH recycling based on the NAD⁺-reducing moiety of the SH immobilised on graphite particles together with a hydrogenase or platinum, with electrons from H₂ passed from the hydrogenase through the graphite to the NAD⁺-reducing moiety. The second involves an electrode modified with the NAD⁺-reducing moiety of the SH, and is demonstrated as an electrochemical NADH recycling system coupled with NADH-dependent pyruvate reduction to lactate by lactate dehydrogenase. The ability of variants of the SH to catalyse NADP⁺ reduction suggests that it may also be possible to use these systems for recycling NADPH for catalysis of important biotransformation reactions by NADPH-dependent dehydrogenases.